Botox
Allergan acquires neurotoxin specialist Bonti in $195m deal
September 17, 2018Sales and Marketing Allergan, Bonti, Botox, Neurotoxin, acquisition, deal
The Dublin-headquartered multinational Allergan have agreed to acquire the clinical stage biotech Bonti in a deal worth more than $195 …
Top Ten most popular articles on Pharmafile.com this week
March 2, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Alzheimer's, AstraZeneca, Botox, Celgene, EMA, FDA, Merck, Mylan, Pfizer, Roche, Takeda, ipsen, vaccines
We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …
Mylan looks to muscle in on Allergan’s Botox territory
March 1, 2018Sales and Marketing Botox, Mylan, Revance Therapeutics, biotech, drugs, epipen, pharma, pharmaceutical
Mylan announced, alongside its financials, that it had signed a global collaboration and licensing agreement with Revance Therapeutics to partner …
Allergan says its double chin correction therapy Belkyra gets positive opinion from Swedish regulators
July 4, 2016Research and Development, Sales and Marketing Allergan, Belkyra, Botox, EU, Sweden, double chin, drug trial
Botox maker Allergan (NYSE: AGN) said it has received a positive opinion from the Swedish Medical Products Agency for its …
Actavis changes its name to Allergan
June 16, 2015Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Valeant
Actavis has now officially changed its name to Allergan following the Ireland-based company’s recent acquisition of the botox maker. This …
Actavis buys Allergan for $66 billion
November 18, 2014Medical Communications, Sales and Marketing Actavis, Allergan, Botox, Canada, Valeant, merger
The stately dance between Actavis and Allergan has culminated in the former buying the Botox manufacturer in a $66 billion …
Allergan eyeing Actavis buyout
November 13, 2014Medical Communications, Research and Development, Sales and Marketing Actavis, Allergan, Botox, Valeant, acquisition, buyout, merger
Allergan is attempting to block a recent Valeant hostile takeover bid by seeking the rumoured alternative merger deal with Actavis, …
Allergan slashes 1,500 jobs
July 22, 2014Research and Development, Sales and Marketing Allergan, Botox, Jobs, cuts, valiant
Allergan is to cut 1,500 jobs as part of a restructure which it believes will make pre-tax savings of around …
Valeant goes hostile over Allergan hunt
June 19, 2014Sales and Marketing Allergan, Botox, Valeant, hostile, takeover
Valeant Pharmaceuticals has turned hostile in its bid to acquire Botox maker Allergan by employing strong-arm tactics in an attempt …
Allergan rejects Valeant – again
June 11, 2014Research and Development, Sales and Marketing Allergan, Botox, Valeant, pershing, pharma
Allergan and Valeant Pharmaceuticals International are continuing their stately dance around one another – and in the latest move the …
Valeant ‘substantially undervalues’ Allergan
May 13, 2014Sales and Marketing Allergan, Botox, Pfizer, Valeant, buyout, merger
Allergan’s board has issued a defiant, unanimous rejection of the multi-billion dollar takeover offer made public by Valeant last month. In …
Valeant makes $45.7 billion Allergan offer
April 23, 2014Sales and Marketing Allergan, Botox, GSK, Novartis, Pfizer, Valeant, merger, pershing
In the latest proposal in a flurry of merger and acquisition activity in the pharma sector, Valeant Pharmaceuticals International wants …
Allergan reprimanded over Botox promotion
March 19, 2014Medical Communications, Sales and Marketing ABPI, Allergan, Botox, Galderma, PMCPA, vistabel
Allergan has been found guilty of breaching six clauses of the ABPI’s Code of Practice over its market research for …
GSK China probe extends to Botox sales
July 8, 2013Sales and Marketing Botox, China, GSK, whistleblower
GlaxoSmithKline’s woes in China are continuing as the firm’s sales tactics with Botox are put under scrutiny. The London-based firm …
Botox US bladder indication
January 22, 2013Sales and Marketing Allergan, Botox, FDA, bladder
Allergan’s Botox has been given approval by the FDA for the treatment of overactive bladder (OAB) in adults.Botox (onabotulinumtoxinA) has …
Latest content
FibroFind appoints Lee Borthwick as CEO
